The Co-CEOs of Summit Therapeutics discuss the ivonescimab vs Keytruda data that was presented at the 2024 World Conference on Lung Cancer
Bob Duggan and Maky Zanganeh answer questions relating to China derived data, designing U.S. studies, how to scale the development of the drug, and more.
Comentarios